Otsuka Pharmaceutical has started selling Rejoyn, its Food and Drug Administration cleared prescription app that treats the symptoms of major depressive disorder. And it’s hitting the market at a low price that Otsuka hopes will entice many people to give it a try.
Otsuka will make the 6-week treatment available to patients through a prescription from their existing provider or through the treatment’s website where they can connect with a clinician from Wheel Health who can prescribe it. Rejoyn will cost an introductory price of $50 out-of-pocket plus the cost of the optional Wheel consultation. Though no insurers have agreed to cover Rejoyn yet, Otsuka says it will charge them $200.
For context, before it went bankrupt, Pear Therapeutics had charged upwards of $1,000 for its prescription cognitive behavioral therapy apps.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect